Demis Hassabis: How Artificial Intelligence Opens the Doors to Molecular Secrets

One autumn, I sat with Demis Hassabis in an observatory built in London over a hundred years ago. Looking up at the night sky, our conversation about constellations became an opportunity to reflect on the size of the universe and the limitations of human knowledge. But beyond the stars, there is another world, just as vast — much closer to us, at the very core of matter.

Countless possibilities of the molecular world

The number of potential chemical compounds on Earth far exceeds the number of stars in the sky. Scientists estimate that there are about 10 to the power of 60 possible small drug-like molecules, while the observable universe contains only about 10 to the power of 22-24 stars. This comparison best illustrates how monumental a challenge it is to discover new therapies.

The history of medicine teaches us that every breakthrough — from the accidental discovery of penicillin to modern biopharmaceuticals — is a victory over overwhelming obstacles. Demis Hassabis, Nobel laureate and creator of Google DeepMind, understands this reality perfectly. It is precisely the awareness of the scale of the challenge that motivated him to undertake an ambitious endeavor.

Isomorphic Labs: a mission to change the approach to medicine

In 2021, Hassabis founded Isomorphic Labs with the goal of using artificial intelligence to navigate the vast landscape of chemical possibilities. His vision was clear, though seemingly radical — systematically leveraging advanced technology to continuously discover and improve therapies.

However, Demis Hassabis consciously avoids using the word “cure.” Instead, he promotes the idea of building a process — flexible, scalable, and repeatable — capable of responding to new health challenges as they arise. It’s not about completely eliminating diseases but creating a systematic approach supported by artificial intelligence and technological platforms.

“To truly demonstrate the value of this approach, we need to present real proof,” — emphasized Krishna Yeshwant, managing partner at Google Ventures, who was involved in the early stages of Hassabis’s project. For him, one thing is key: discovering own drugs, delivering them to patients, and proving that they actually work.

A new era in drug discovery

Demis Hassabis and his team at Isomorphic Labs are now at a pivotal moment. The drug discovery industry, supported by artificial intelligence, is entering a phase where concrete, tangible results are needed. This is not the time for promises — it’s time for evidence.

If Hassabis’s vision comes to fruition, the implications could go far beyond improving therapies for cancer or autoimmune diseases. We may soon witness the emergence of a revolutionary system — capable of navigating the entire molecular complexity of the human body, discovering solutions for every new disease.

Pushing the boundaries of what is possible in medicine through artificial intelligence — this is the legacy Demis Hassabis is building.